Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor, and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones. Cyanocobalamin will help increase energy.
GIP has decreased food intake and increased energy expenditure, resulting in weight reductions. Combined with a GLP-1 receptor agonist, it has a more significant effect on glucose and body weight effects.